Last reviewed · How we verify

Amyloid polyneuropathy type I — Treatment Landscape & Competitive Intelligence

Amyloid polyneuropathy type I (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Amyloid polyneuropathy type I, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vyndaqel Tafamidis Meglumine Foldrx Pharms Transthyretin stabilizer Transthyretin (TTR) 2019-01-01
Vyndaqel tafamidis Foldrx Pharms tafamidis Transthyretin 2019-01-01
Vyndaqel tafamidis-test Foldrx Pharms tafamidis Transthyretin 2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Foldrx Pharms · 4 drugs in Amyloid polyneuropathy type I

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Amyloid polyneuropathy type I:

Cite this brief

Drug Landscape (2026). Amyloid polyneuropathy type I — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/amyloid-polyneuropathy-type-i. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing